Compare
Trevi Therapeutics, Inc. vs Adicet Bio, Inc. vs Foghorn Therapeutics Inc. vs UroGen Pharma Ltd.
| Latest fiscal year | Trevi Therapeutics, Inc. TRVI | Adicet Bio, Inc. ACET | Foghorn Therapeutics Inc. FHTX | UroGen Pharma Ltd. URGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $30.91M | $109.79M |
| Revenue growth (YoY) | n/a | n/a | +36.8% | +21.4% |
| Gross margin | n/a | n/a | n/a | 88.7% |
| Operating margin | n/a | n/a | -279.5% | -113.7% |
| Net margin | n/a | n/a | -240.3% | -139.8% |
| Net income | -$42.76M | -$116.80M | -$74.28M | -$153.49M |
| EPS (Diluted) | -$0.32 | -$16.95 | -$1.18 | n/a |
| Operating cash flow | -$42.09M | -$95.25M | -$86.10M | -$162.44M |
| Free cash flow | -$42.10M | -$96.98M | -$86.15M | -$162.73M |
| Cash & equivalents | $18.91M | $38.92M | $80.88M | $110.75M |
| Total assets | $193.44M | $192.35M | $198.10M | $200.46M |
| Total liabilities | $10.20M | $33.15M | $306.60M | $305.93M |
| Shareholders' equity | $183.24M | $159.21M | -$108.50M | -$105.47M |
| Return on year-end equity | -23.3% | -73.4% | n/a | n/a |
| Shares outstanding | 128.31M | 9.59M | 56.66M | 48.35M |
Revenue, most recent five fiscal years
| Fiscal year | Trevi Therapeutics, Inc. | Adicet Bio, Inc. | Foghorn Therapeutics Inc. | UroGen Pharma Ltd. |
|---|---|---|---|---|
| Latest | n/a | n/a | $30.91M Ended 2025-12-31 | $109.79M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $22.60M Ended 2024-12-31 | $90.40M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $34.16M Ended 2023-12-31 | $82.71M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $19.23M Ended 2022-12-31 | $64.36M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.32M Ended 2021-12-31 | $48.04M Ended 2021-12-31 |